Cargando...
免疫检查点抑制剂治疗少见突变非小细胞肺癌疗效的研究进展
Over the past several decades, advances in driven targeted therapy has revolutionized the management of oncogene-driven non-small cell lung cancer (NSCLC). However, there are only a few targeted drugs available for patients with rare mutations, such as BRAF, HER2, MET, RET, etc. In recent years, imm...
Gardado en:
| Publicado en: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7849033/ https://ncbi.nlm.nih.gov/pubmed/33478186 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.41 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|